Harada T, Kan N, Okino T, Ichinose Y, Moriguchi Y, Li L, Sugie T, Ohgaki K, Imamura M
First Department of Surgery, Faculty of Medicine, Kyoto University, Japan.
Biotherapy. 1993;7(2):91-9. doi: 10.1007/BF01877732.
This study shows that intraperitoneal injection of interleukin-1 (IL-1), followed by interleukin-2 (IL-2), can effectively eradicate murine ascitic tumor cells. This antitumor effect of IL-1 and IL-2 was abolished when administration of IL-2 preceded that of IL-1. Solid tumors inoculated subcutaneously (s.c.) into the back of mice were also sensitive to this combined i.p. therapy, indicating a systemically-operating antitumor mechanism. Splenocytes from tumor-bearing mice treated with IL-1 followed by IL-2 showed a strong tumor-neutralizing activity. The population responsible proved to be Lyt2.2 (CD8)-positive cells.
本研究表明，腹腔注射白细胞介素-1（IL-1），随后注射白细胞介素-2（IL-2），可有效根除小鼠腹水肿瘤细胞。当IL-2的给药先于IL-1时，IL-1和IL-2的这种抗肿瘤作用被消除。皮下（s.c.）接种于小鼠背部的实体瘤对这种联合腹腔内治疗也敏感，表明存在一种全身性作用的抗肿瘤机制。先用IL-1然后用IL-2治疗的荷瘤小鼠的脾细胞表现出强大的肿瘤中和活性。结果证明起作用的细胞群是Lyt2.2（CD8）阳性细胞。
